Cardiovascular Today—July 9, 2026

LucidQuest

8 hours ago

This week’s Cardiovascular update highlights evolving clinical evidence, guideline refinement, imaging innovation, registry insights and regulatory developments across cardiovascular care.

In Today’s Newsletter

Dive deeper

🫀 SWEDEHEART pregnancy outcomes after bioprosthetic AVR [1] [Sweden • 03 Jul 2026]

https://cardiovascularnews.com/study-finds-favourable-delivery-outcomes-following-bioprosthetic-aortic-valve-replacement-for-women-contemplating-future-pregnancy/
Context: SWEDEHEART analysis included women aged 18–40 years undergoing SAVR in Sweden from 1997–2024.
Key point: Bioprosthetic AVR was described as a reasonable option for women with aortic valve disease contemplating future pregnancy.
Implication: May influence shared decision-making and valve selection pending individualized risk assessment.

🫀 Triclip real-world TVT registry outcomes [2] [US • 02 Jul 2026]

https://cardiovascularnews.com/registry-data-offer-real-world-comparison-of-triclip-against-randomised-trial-performance/
Context: STS/ACC TVT registry data covered more than 3,000 US Triclip TEER procedures after FDA approval.
Key point: Thirty-day outcomes showed high procedural success, low short-term adverse-event rates, and TR reduction similar to trial findings.
Implication: May influence prescriber choice and payer reviews pending full data.

📘 Second Universal Definition of Heart Failure [3] [Global • 01 Jul 2026]

https://cardiovascularnews.com/expert-consensus-statement-updates-heart-failure-definition/
Context: AHA, ACC, ESC and WHF issued an updated consensus definition with HFSA, HFA and JHFS collaboration.
Key point: The framework emphasizes causes, stages, trajectories, geographic variation and more actionable ejection-fraction categories.
Implication: Could standardize research, guideline development and earlier risk-based intervention.

⚙️ ICARE IVL versus rotational atherectomy trial [4] [07 Jul 2026]

https://cardiovascularnews.com/ivl-matches-rotational-atherectomy-for-plaque-preparation-in-severely-calcified-lesions/
Context: ICARE randomized 169 patients with chronic coronary syndrome and moderate-to-severely calcified lesions.
Key point: IVL was non-inferior to rotational atherectomy for acute post-PCI minimal stent area.
Implication: May influence operator choice where both plaque-modification strategies are available.

🧠 Elucid CCTA 3.0 platform at SCCT 2026 [5] [US • 06 Jul 2026]

https://www.businesswire.com/news/home/20260706232077/en/Elucid-to-Showcase-CCTA-Vision-at-SCCT-2026-Defining-the-Future-of-Personalized-Cardiovascular-Care
Context: Elucid plans to showcase AI-powered CCTA analysis at SCCT 2026 in Chula Vista, California.
Key point: The company will present plaque analysis, plaque-based FFR-CT and stenosis quantification, with FFR-CT and stenosis under FDA review.
Implication: Signals pipeline investment and modality expansion.

🧠 Nanox.AI cardiac CT data at SCCT 2026 [6] [US/Israel • 07 Jul 2026]

https://www.globenewswire.com/news-release/2026/07/07/3323156/0/en/new-clinical-study-data-featuring-nanox-ai-cardiac-solution-to-be-presented-at-scct-2026.html
Context: Nanox.AI will present SCCT 2026 abstracts involving HealthCCSng and coronary artery calcium assessment.
Key point: Planned data include AI INFORM trial findings and a multi-site comparison with expert visual assessment.
Implication: May expand screening, initiation, and follow-up at scale.

💊 ACC scientific statement on DOAC therapy [7] [US • 07 Jul 2026]

https://cardiovascularbusiness.com/topics/clinical/pharmaceutics/acc-takes-doac-use-new-scientific-statement
Context: ACC issued a scientific statement on DOAC therapy for primary and secondary prevention of thrombotic events.
Key point: The statement addresses dosing, monitoring, special populations, bleeding risk, adherence and cost barriers.
Implication: Could standardize implementation and reduce inappropriate underuse or dosing.

🩺 FDA labeling update for Gore EVAR devices [8] [US • 07 Jul 2026]

https://cardiovascularbusiness.com/topics/clinical/vascular-endovascular/fda-approves-labeling-change-gore-evar-devices
Context: FDA approved updated labeling for Gore Excluder AAA Endoprosthesis and Excluder Conformable AAA Endoprosthesis.
Key point: The prior warning about ruptured aneurysms was removed, with new data added for ruptured AAA use.
Implication: Introduces clearer labeling that may support urgent EVAR decision-making.

Why it matters

Cardiovascular evidence is shifting toward registry-backed, real-world validation for devices such as Triclip and Gore EVAR.
Imaging AI remains a major SCCT 2026 theme, with Elucid and Nanox.AI positioning CT as a preventive-care platform.
Definitions and consensus statements may reshape downstream guidelines, particularly for heart failure and anticoagulation.
Head-to-head interventional data, such as ICARE, can help refine device selection in complex coronary anatomy.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Cardiovascular archive on our research hub page

FAQ

What did SWEDEHEART report about bioprosthetic AVR and pregnancy?

SWEDEHEART reported favourable delivery outcomes in women of reproductive age who received bioprosthetic AVR, alongside high reintervention rates. The source frames this as useful for shared decision-making. [1]

How did Triclip perform in early US real-world data?

The STS/ACC TVT registry showed high procedural success and low 30-day event rates for Triclip TEER in severe TR. Echo and clinical outcomes were site-reported, with short-term follow-up only. [2]

What changed in the Second Universal Definition of Heart Failure?

The new definition emphasizes earlier risk identification, disease causes, dynamic trajectories and clinically actionable ejection-fraction categories. It is intended to support more consistent diagnosis and care. [3]

What did ICARE show for IVL versus rotational atherectomy?

ICARE found IVL non-inferior to rotational atherectomy for post-stent minimal stent area in calcified coronary lesions. The trial was powered for an imaging endpoint, not clinical outcomes. [4]

What is Elucid presenting at SCCT 2026?

Elucid plans to showcase its AI-powered CCTA platform, including plaque analysis, plaque-based FFR-CT and stenosis quantification. FFR-CT and stenosis are described as under FDA review. [5]

What does the Gore EVAR labeling update mean?

FDA removed a prior warning that Gore Excluder devices had not been evaluated for ruptured aneurysms. The update adds data supporting use in ruptured AAA care. [8]

Entities / Keywords

SWEDEHEART, surgical aortic valve replacement, SAVR, bioprosthetic AVR, mechanical AVR, pregnancy, reintervention
Triclip, Abbott, tricuspid TEER, severe tricuspid regurgitation, TRILUMINATE, Tri.Fr, STS/ACC TVT registry
AHA, ACC, ESC, WHF, HFSA, HFA, JHFS, Second Universal Definition of Heart Failure, LVEF
ICARE, intravascular lithotripsy, IVL, rotational atherectomy, PCI, calcified coronary lesions, OFDI, MSA
Elucid, CCTA 3.0, Plaque-IQ, FFR-CT, stenosis quantification, plaque analysis, SCCT 2026
Nanox.AI, Nanox Imaging, HealthCCSng, AI INFORM, coronary artery calcium, routine CT, preventive care
DOACs, ACC scientific statement, anticoagulation, AFib, VTE, CKD, bleeding risk, factor XI agents
Gore, Excluder AAA Endoprosthesis, Excluder Conformable AAA Endoprosthesis, EVAR, AAA, ruptured AAA, FDA